Zai Lab Limited Unsponsored ADR $ZLAB Shares Purchased by Invesco Ltd.

Invesco Ltd. boosted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 23.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,544 shares of the company’s stock after buying an additional 10,204 shares during the quarter. Invesco Ltd.’s holdings in Zai Lab were worth $1,971,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ZLAB. RTW Investments LP acquired a new position in Zai Lab in the 4th quarter worth $65,714,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company’s stock worth $77,058,000 after buying an additional 2,127,598 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Zai Lab by 63.6% in the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company’s stock worth $104,257,000 after buying an additional 1,121,856 shares in the last quarter. MPM Bioimpact LLC bought a new stake in shares of Zai Lab in the 4th quarter worth about $20,952,000. Finally, Jennison Associates LLC bought a new stake in shares of Zai Lab in the 1st quarter worth about $25,743,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

Insiders Place Their Bets

In other news, insider Rafael Amado sold 3,000 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $35.00, for a total value of $105,000.00. Following the completion of the transaction, the insider directly owned 42,178 shares in the company, valued at $1,476,230. This trade represents a 6.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Joshua L. Smiley sold 6,641 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $36.24, for a total transaction of $240,669.84. Following the completion of the transaction, the insider owned 76,604 shares of the company’s stock, valued at $2,776,128.96. This trade represents a 7.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 215,710 shares of company stock valued at $7,589,684. 4.96% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ZLAB shares. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the stock an “outperform” rating in a research report on Monday, June 30th. Jefferies Financial Group started coverage on shares of Zai Lab in a research report on Monday, August 25th. They issued a “buy” rating and a $52.00 target price for the company. Wall Street Zen downgraded shares of Zai Lab from a “buy” rating to a “hold” rating in a research report on Friday, June 27th. Finally, Citigroup reaffirmed a “buy” rating and set a $69.00 price objective (up previously from $66.00) on shares of Zai Lab in a research report on Monday, August 11th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $56.35.

Zai Lab Stock Up 2.7%

Zai Lab stock opened at $33.10 on Monday. The firm has a 50-day moving average price of $35.68 and a two-hundred day moving average price of $34.04. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of -16.23 and a beta of 1.04. Zai Lab Limited Unsponsored ADR has a 52-week low of $18.60 and a 52-week high of $44.34.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.37). The firm had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. Research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.